As research continues to unfold and unveil further insights, the trajectory of cancer treatment is poised for continued evolution, where PD-1/PD-L1 inhibitors remain at the forefront of innovative strategies aimed at ameliorating the prognosis and quality of life for affected individuals. Although PD-1/PDL-1 inhibitors have demonstrated notable achievements, they are not exempt from encountering obstacles. This evidence concerns the gene CD274 and cancer.